One Health intelligence becomes useful at the handoff.
A shared platform can make a signal visible. It cannot, by itself, decide whether the signal is verified, which authority owns the response, where a specimen should go, whether results are comparable or how an alert becomes an authorised public-health action. Those decisions live in the handoffs between institutions.
The One Health High-Level Expert Panel analysed more than 260 inputs and produced 10 interconnected recommendations for implementing the Quadripartite One Health Joint Plan of Action. WHO groups the recommendations across five domains: governance, finance, data, community engagement and workforce capacity. WHO describes them as a roadmap for moving One Health from a conceptual framework to coordinated action.
A shared framework now has a longer implementation horizon
FAO, UNEP, WHO and WOAH extended the One Health Joint Plan of Action from its original 2022–2026 period through 2029. The organisations say the extension is intended to give countries greater predictability for planning, implementing and scaling national priorities under a common framework. A structured review will take stock of progress, lessons and emerging needs.
Vision interpretation: predictability is valuable only when it reaches operating procedures and budgets. National plans need named owners, decision thresholds, laboratory roles, data-sharing rules, financing for recurring quality activities and measurable service levels. A cross-sector committee without an executable pathway can coordinate discussion while leaving the next specimen or alert without a destination.
A signal is not yet a verified event
The upgraded GLEWS+ platform, launched in March 2026, gives FAO, WHO and WOAH a restricted channel to share information about emerging threats at the human–animal–ecosystem interface. The organisations report that signals meeting agreed criteria are verified, analysed and assessed by their One Health intelligence officers; this work may lead to situation updates, forecasts, joint risk assessments or early-warning alerts.
Vision interpretation: national systems should preserve the same distinction between detection and decision. Each signal needs its origin, timestamp, confidence, verification status, responsible authority and revision history. Unverified information can guide investigation, but it should not silently become a confirmed laboratory event or procurement trigger.
The diagnostic handoff begins before the sample moves
Human-health, veterinary, wildlife, food-safety and environmental programmes may use different case definitions, identifiers, specimen types, transport networks and legal authorities. A handoff fails when these differences are discovered only after collection.
Vision interpretation: the referral design should define which laboratory may screen, which may confirm, who may collect each specimen, what packaging and biosafety controls apply, which metadata travel with it, how custody is recorded and what happens after an invalid, inconclusive or discordant result. A common event identifier should link the field investigation, specimen, test, result and authorised response without erasing the source system's record.
Comparable data require comparable quality evidence
An FAO–IZSVe laboratory-capacity programme covering avian influenza, Newcastle disease and rabies includes confirmatory testing, molecular characterisation, proficiency-testing panels, troubleshooting support and positive and negative reference controls. FAO links these activities to stronger quality assurance and more reliable surveillance data.
Vision interpretation: interoperability is not only a software problem. Before results from different sectors or sites are combined, authorities should know the method, specimen basis, control status, operator competency, lot and instrument traceability, external quality evidence and confirmation rule behind each result. A common dashboard should not imply comparability that the underlying methods and quality systems have not demonstrated.
Operational readiness is built through repeated practice
FAO reported a five-day brucellosis laboratory training at the wildlife–livestock interface in the Kavango–Zambezi region. The programme covered biosafety, quality assurance, reagent preparation, sample processing, test execution, quality control, troubleshooting and interpretation, while Zimbabwe's Central Veterinary Laboratory was identified for continuing mentorship, quality assurance and referral support.
Vision interpretation: a workshop is a starting point, not sustained capacity. Readiness should be demonstrated through supervised practice, competency assessment, controlled documents, reagent standardisation, routine controls, proficiency testing, maintenance, referral drills and corrective-action follow-up. The reference laboratory's mentoring and escalation role should be funded and measured.
One dashboard should not erase source differences
The public GLEWS+ dashboard states that it shows only a subset of officially reported events. It also warns that different reporting and publication timelines can create duplication or delay between sources and that the dashboard is intended for general information.
Vision interpretation: public summaries and operational dashboards should retain source authority, publication date, event date, geographic scope and version. Reconciliation rules should identify duplicates without overwriting original records. Missing data should remain visible, and retrospective corrections should be auditable.
Localisation should shorten the response distance
Local capability can reduce transport, maintenance and replenishment delays, and can deepen workforce capacity. It does not automatically make methods equivalent, remove regulatory controls or authorise exchange of sensitive health data across sectors.
Vision interpretation: localisation should target verified bottlenecks: specimen materials, compliant packaging, selected consumables, reference controls, equipment service, secure data integration, training and quality oversight. Technology transfer should preserve method identity, supplier qualification, validation, lot release, change control and the competent authority's role. Local production volume is useful only when it supports a defined and authorised service.
The Vision Biotechnology handoff gate
Before a One Health signal is treated as decision-ready, partners should be able to answer seven questions:
- Which authority owns the signal, verification decision and response at each stage?
- Which laboratories are authorised to screen, confirm, refer and release results?
- Can a unique identifier connect the event, specimen, method, result and action while preserving source records?
- Are biosafety, packaging, transport, acceptance and rejection rules documented across sectors?
- Can participating laboratories show controls, competency, traceability and external quality evidence appropriate to their role?
- Do dashboards preserve source dates, uncertainty, missingness, duplication and revision history?
- Can local capability expand without bypassing validation, quality, data-governance or regulatory controls?
Vision Biotechnology can support qualified partners with cross-sector pathway mapping, laboratory and equipment planning, quality-system architecture, training requirements, supply continuity and controlled localisation roadmaps within the applicable national framework. This support does not replace competent authorities, laboratory confirmation or the mandates of human, animal and environmental health institutions.
Invest in the handoffs as deliberately as the platform. One Health intelligence becomes operational when a verified signal can move through a safe specimen route, a trusted laboratory process, an authorised data pathway and a funded response without losing identity, context or accountability.
Reporting limitations
The cited sources describe global frameworks, selected international systems and specific capacity-building examples. They do not establish that every country has implemented the same governance, laboratory, data-sharing or financing arrangements; they do not measure the completeness, timeliness or performance of every participating surveillance network. The GLEWS+ public dashboard is explicitly a subset and may contain duplicated or delayed events because source timelines differ.
Primary sources
This article separates WHO, FAO and WOAH-published information from Vision Biotechnology interpretation. It provides general public-health, veterinary-laboratory, quality-system, data-governance and localisation information; it is not medical or veterinary advice, a diagnostic recommendation, regulatory approval or a claim about any Vision product. Competent authorities and applicable national procedures remain controlling.